THE THERAPY OF MULTIPLE SCLEROSIS WITH NUKLEO-СMF FORTE AND PK-MERZ MULTIDIRECTIONAL DRUGS
Multiple sclerosis − the multifactorial autoimmune disease affecting the head and spinal cord, demanding application in therapy of medicines of multidirectional action. In the group of patients, we used the drug «Nucleo-CMP Forte», which provides phosphate groups needed to combine with sugars to form ceramides and cerebrosides phosphatidic acids, which form the basis of glycerophospholipids and sphingomyelin. The second drug of choice was the «PK-Merz» blocking NMDA-glutamate receptors which are leading in the pathogenesis of axonal degeneration. This choice is due to the direct impact on the process of demyelination on the one hand, and indirect exposure to the drug «PC-Merz» aimed at reducing the degenerative processes in the glial tissue involved in the synthesis of myelin, on the other hand. Clinical studies have been conducted in 15 patients suffering from a secondary-progressive course of MS. The patients were divided into two groups. The 1st group included 8 people receiving conventional therapy (hormones, vitamins B antiplatelet agents). The second group included 7 persons. The scheme of conventional treatment included drugs «PC-Merz» in a single dose of 100mg. (a daily dose of 300 mg.) −30 days «Nucleo-CMP forte» − 2 capsules a day, for 30 days. We suggest that the one-way action in one system of different groups of drugs, affecting the process of demyelination and axonal degeneration in multiple sclerosis, may have a better chance to improve the effectiveness of therapy.
Gubarev YuD, Chefranova ZhYu, Yatsenko EA. The therapy of multiple sclerosis with NUKLEO-СMF FORTE and PK-MERZ multidirectional drugs. Research Result. Medicine and Pharmacy Series. 2015;1(4):13-18 (In Russian). DOI: 10.18413 / 2313-8955-2015-1-4-13-18
While nobody left any comments to this publication.
You can be first.
L.V. Araslanova, A.V. Shepelev // Materials of Scientific Conference «Nevsky Radiological Forum: from the Past to the Future. St. Petersburg. 2003. Pp 71-72.
V.A. Demkina, V.B. Gervazieva // Neuroimmunology. Volume 3, №1. 2005. Pp. 28-32.
of IFNgamma and IL-12 by endogenous IL-10 in progressive MS / KE Balashov, M. Comabella, T. Ohashi et al. // Neurology.2000. Vol.55, N2. P. 192-198.